Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000‐patient 15‐year experience
Riad Salem(Northwestern University), Robert J. Lewandowski(Society of Interventional Radiology), Ryan Hickey(New York University), Al B. Benson(Northwestern University), Juan Carlos Caicedo(Broad Institute), Bassel Atassi(Society of Interventional Radiology), Joseph R. Kallini(Northwestern University), Mary F. Mulcahy(Northwestern University), R. Mora(Northwestern Memorial Hospital), S. Mouli(Northwestern University), Nadine Abouchaleh(Northwestern Memorial Hospital), Kush Desai(Northwestern University), Rehan Ali(Northwestern Memorial Hospital), Michaël Abécassis(University of Arizona), Vahid Yaghmai(Virginia Commonwealth University Medical Center), Steven L. Flamm(Northwestern University), Ahsun Riaz(Northwestern University), Frank H. Miller(Northwestern University), Laura Kulik(Northwestern University), Ali Al Asadi(Northwestern Memorial Hospital), Bartley Thornburg(Northwestern Memorial Hospital), Daniel Ganger(Northwestern University), Kent T. Sato(Society of Interventional Radiology), Michaël Vouche(Université Libre de Bruxelles), Ali Habib(Northwestern University), Ahmed Gabr(Northwestern University)
Cited by 235
Related Papers
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
|Hepatology|2018|4.7k
AASLD guidelines for the treatment of hepatocellular carcinoma
|Hepatology|2017|4.2k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
|Journal of Clinical Oncology|2007|2.3k
Hepatobiliary Cancers
|Journal of the National Comprehensive Cancer Network|2009|2.3k